FDA Approves First Gene Therapy For High-Risk, Non-Muscle-Invasive Bladder Cancer
The U.S. Food and Drug Administration has approved Ferring Pharmaceuticals A/S’s Adstiladrin (nadofaragene firadenovec-vncg) to treat high-risk, non-muscle-invasive bladder cancer. Adstiladrin is a non-replicating, i.e., cannot multiply in human cells, … Read More
